For the year ending 2025-12-31, PCSA had $4,345,630 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -13,563,834 |
| Depreciation | 1,204 |
| Non-cash lease expense for right-of-use assets | 70,677 |
| Unrealized gain on digital assets at fair value | 295,180 |
| Stock-based compensation | 857,550 |
| Prepaid expenses and other | -834,651 |
| Operating lease liability | -66,905 |
| Accounts payable | 175,916 |
| Accrued expenses | 600,726 |
| Net cash used in operating activities | -11,385,195 |
| Purchase of digital asset | 850,000 |
| Net cash used in investing activities | -850,000 |
| Net proceeds from issuance of common stock | 16,597,831 |
| Shares withheld to pay taxes on stock-based compensation | 10,404 |
| Payment of finance lease obligation | 6,602 |
| Net cash provided by financing activities | 16,580,825 |
| Net increase (decrease) in cash and cash equivalents | 4,345,630 |
| Cash and cash equivalents - beginning of year | 1,191,325 |
| Cash and cash equivalents - end of year | 5,536,955 |
Processa Pharmaceuticals, Inc. (PCSA)
Processa Pharmaceuticals, Inc. (PCSA)